BRAF and melanoma: This has prompted clinical trials incorporating CDK4/6i into existing therapeutic protocols for melanoma, for example by combining CDK4/6i with current standard-of-care targeted inhibitors of oncogenic BRAF and/or MEK (NCT01719380, NCT01777776, NCT04720768)8.